Stewart Jeffrey Ryan 4

4 · AbbVie Inc. · Filed Apr 2, 2025

Form 4

Period: 2025-03-31

EVP, CHIEF COMMERCIAL OFFICER

Transactions

Sale
Common Stock, $0.01 par value
2025-03-31$209.49/sh−25,700$5,383,893→ 86,366 total
Sale
Common Stock, $0.01 par value
2025-03-31$210.54/sh−33,132$6,975,611→ 53,234 total
Exercise/Conversion
Option (Right to Buy)
2025-03-31$79.02/sh−25,700$2,030,814→ 0 total
Exercise: $79.02Exp: 2029-02-20→ Common Stock (25,700 underlying)
Exercise/Conversion
Common Stock, $0.01 par value
2025-03-31$79.02/sh+25,700$2,030,814→ 112,066 total

Holdings

Footnotes (4)

[F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.43 to $209.60, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.54 to $210.63, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The reporting person disclaims beneficial ownership of all securities held by his spouse.
[F4]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Documents

1 file